Tirofiban hydrochloride monohydrate

SKU: orb1305344

Description

Tirofiban hydrochloride monohydrate (MK-383) is a potent, non-peptide antagonist of the glycoprotein IIb/IIIa receptor. It is widely used in research to study platelet aggregation inhibition, serving as a key tool for in vitro assays and in vivo models of thrombosis and cardiovascular disease.

Research Area

Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 150915-40-5
• MW: 495.07
• Purity: >99.99% (May vary between batches)
• Formula: C₂₂H₃₉ClN₂O₆S
• SMILES: O.Cl.CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O
• Target: ATPase,Integrin
• Solubility: DMSO:250 mg/mL (504.98 mM)

Bioactivity

• Target IC50:
  Thrombin:5,000 ng/ml|Collagen:200 ng/ml|ADP:70 ng/ml
• In Vivo:
  METHODS: Rats were intravenously injected with Tirofiban（MK383） hydrochloride monohydrate (200 μg/kg). Fifteen minutes later, the left renal pedicle was occluded with a small microvascular forceps, and renal ischemia was induced for 45 minutes. Blood was collected 24 hours after reperfusion, and the left kidney was taken for analysis. RESULTS Tirofiban can reduce SCR and BUN levels in I/R-injured kidneys, improve renal tissue pathological changes, and reduce ROS generation, cell apoptosis, and leukocyte infiltration. METHODS: 60 μg/kg Tirofiban was administered as an intravenous bolus injection through the tail vein of rats 30 minutes before reperfusion, and the cardiac function of the rats was observed. RESULTS Tirofiban improved cardiac function, with lower left ventricular end-systolic blood pressure levels, left ventricular pressure maximum change rates of increase and decrease, heart rate, and left ventricular end-diastolic pressure levels.
• In Vitro:
  METHODS: HUVEC cells were cultured in 24-well plates. The effect of 0.12, 0.25, 1, and 3 μg/ml Tirofiban（MK383） hydrochloride monohydrate on cell growth was determined using cell counting method. Cells were harvested after 72 h and counted using trypan blue. RESULTS At a concentration of 0.25 μg/ml, the number of cells in the Tirofiban group increased compared with the group without Tirofiban. Tirofiban can induce the growth of HUVEC cells. METHODS:HUVEC cells were treated with Tirofiban (1mg/mL) at different time points (0, 1, 2, 3, 4 and 5 hours). RESULTS After Tirofiban treatment, the amount of VEGF produced by HUVECs gradually increased and reached a peak at 2 hours.

Storage & Handling

• Storage: keep away from direct sunlight,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ACSs, ADP, MK 383 Hydrochloride, MK-383 Hydrochloride, MK-383 Hydrochloride monohydrate, Integrin, L700462 hydrochloride, GPIIb/IIIa, HAEC, Tirofiban Hydrochloride monohydrate, Tirofiban Hydrochloride, VEGF

Compound Identifiers

PubChem CID

60946